NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Vor Biopharma Inc. (VOR) Stock Analysis

Vor Biopharma Inc. (VOR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VOR

$18.94

−$0.09 (−0.47%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VOR with… →

VOR Key Statistics

As of Oct 21, 2026
Trading
Open
$19.18
Previous Close
$19.03
Day's Range
18.79–19.78
52-Week Range
6.50–28.66
Volume
817.35K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.78
Valuation
Market Cap
$1.12B
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$695.98M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
59.16M
1-Year Return
−31.80%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
957.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VOR closed at $18.94, −31.80% over 1 year.

Vor Biopharma Inc. (VOR) has a market capitalization of $1.12B.

In fiscal 2025, VOR reported revenue of $0.00.

VOR Stock Return by Calendar Year

Vor Biopharma Inc. (VOR) return since Feb 2021: what $10,000 became

1 year
$10,000 $6,820
−31.80%
5 years
$10,000 $597
−94.03%
Since Feb 2021
$10,000 $253
−97.47%

If you had invested $10,000 in Vor Biopharma Inc. (VOR) at the close on February 5, 2021, the earliest close on record here, it would have been worth $253 at the close on October 21, 2026: −97.47% in total, −47.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+44.80%
2025−41.08%
2024−50.67%
2023−66.17%
2022−42.77%
2021 (partial year)−69.01%

As of October 21, 2026.

VOR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$695.98M—
2024$0.00−$116.91M—
2023$0.00−$117.86M—
2022$0.00−$92.09M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$371.64M−$695.98M—
2024$0.00—−$121.19M−$116.91M—
2023$0.00—−$126.04M−$117.86M—
2022$0.00—−$93.42M−$92.09M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vor Biopharma Inc. (VOR) at $1.12B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 76 employees.

VOR last closed at $18.94 on October 21, 2026. That is −$0.09 (−0.47%) against the previous close. Over the past 52 weeks the price has ranged from $6.50 to $28.66. The latest close sits 191.38% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $695.98M.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

Over the trailing twelve months the total return is −31.80%. Measured over 5 years, that is −43.09% a year compounded. Beta against the wider market is reported at 1.78. Annualized volatility over the trailing 5 years is 116.14%.

Growth & Income

No dividend is on file for VOR.

So far in 2026 the total return is +44.80%. The strongest complete calendar year on file is 2025 at −41.08%; the weakest is 2023 at −66.17%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Vor Biopharma Inc. (VOR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vor Biopharma Inc. VOR $1.12B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Vor Biopharma Inc.

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Visit website →